278
Views
4
CrossRef citations to date
0
Altmetric
Review

Potential epigenomic co-management in rare diseases and epigenetic therapy

Pages 752-780 | Received 07 Dec 2017, Accepted 11 Mar 2019, Published online: 11 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Benjamin J. Maldonato, Ana G. Vergara, Jaydeep Yadav, Sarah M. Glass, Erickson M. Paragas, Dongying Li, Philip Lazarus, Joseph L. McClay, Baitang Ning, Ann K. Daly & Laura E. Russell. (2022) Epigenetics in drug disposition & drug therapy: symposium report of the 24th North American meeting of the International Society for the Study of Xenobiotics (ISSX). Drug Metabolism Reviews 54:3, pages 318-330.
Read now

Articles from other publishers (3)

Sandra Brasil, Cátia José Neves, Tatiana Rijoff, Marta Falcão, Gonçalo Valadão, Paula A. Videira & Vanessa dos Reis Ferreira. (2021) Artificial Intelligence in Epigenetic Studies: Shedding Light on Rare Diseases. Frontiers in Molecular Biosciences 8.
Crossref
Chiara Papulino, Ugo Chianese, Maria Maddalena Nicoletti, Rosaria Benedetti & Lucia Altucci. (2020) Preclinical and Clinical Epigenetic-Based Reconsideration of Beckwith-Wiedemann Syndrome. Frontiers in Genetics 11.
Crossref
Khue Vu Nguyen. (2019) β-Amyloid precursor protein (APP) and the human diseases. AIMS Neuroscience 6:4, pages 273-281.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.